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A B S T R A C TObjectives: To understand how people value information from diag-
nostic technologies, we reviewed and analyzed published willingness-
to-pay (WTP) studies on the topic. Methods: We searched PubMed for
English-language articles related to WTP for diagnostic laboratory
tests published from 1985 through 2011. We characterized methodo-
logical differences across studies, examined individual- and
technology-level factors associated with WTP, and summarized
median WTP values across different diagnostic tests. Results: We
identiﬁed 66 relevant WTP studies. Half focused on oncology, while
others analyzed infectious diseases (n ¼ 11, 16.1%) and obstetric or
gynecological conditions (n ¼ 8, 11.7%), among others. Most laboratory
tests included in studies were biological samples/genetic testing (n ¼
44, 61.1%) or imaging tests (n ¼ 23, 31.9%). Approximately one third of
the analyses (n ¼ 20, 30.3%) used discrete-choice questions to elicit
WTP values. Higher income, education, disease severity, perceived
disease risk, family history, and more accurate tests were in generalsee front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.04.005
tsmedicalcenter.org.
ondence to: Pei-Jung Lin, Center for the Evaluation
s, Tufts Medical Center, 800 Washington Street, Bassociated with higher WTP values for diagnostic information. Of the
44 studies with median WTP values available, most reported a median
WTP value below $100. The median WTP value for colon or colorectal
cancer screening ranged from below $100 to over $1000. Conclusions:
The contingent valuation literature in diagnostics has grown rapidly,
and suggests that many respondents place considerable value on
diagnostic information. There exists, however, great variation in
studies with respect to the type of technologies and diseases assessed,
respondent characteristics, and study methodology. The perceived
value of diagnostic technologies is also inﬂuenced by the study design
and elicitation methods.
Keywords: contingent valuation, diagnostics, review, willingness to
pay.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Predictive testing, one of the fastest growing areas of health care,
has been shown to be one of several important drivers of health
cost increases in the United States [1,2]. In moving toward cost-
conscious care, the value of screening and diagnostic tests has
been central to policy discussions [3]. Many studies have exam-
ined the value of test information by using a conventional cost-
effectiveness framework [4]. Under this framework, information
from diagnostics is typically valued exclusively for its ability to
improve medical decision making and subsequent outcomes. In
practice, however, patients may value information from a diag-
nostic test whether or not the information effects treatment
change [5,6]. For example, test information may reduce uncer-
tainty and provide reassurance, assist in life-planning decisions,
and beneﬁt future treatment decisions among the patient’s
family.
Contingent valuation, a standard economic measure of
willingness to pay (WTP) for health interventions, offersresearchers ﬂexibility to investigate how people value a wide
range of health beneﬁts. WTP for a speciﬁed health improve-
ment is deﬁned as the maximum amount of money an
individual could pay for the health improvement and still
consider himself or herself better off [7]. WTP valuation can
be used in cost-beneﬁt analysis by estimating the cost of the
intervention against the WTP values of the indicated improve-
ment [8,9]. Those instances in which the WTP value is greater
than the cost of the invention provide evidence of consumer
surplus [10]. Observers in the ﬁeld have identiﬁed challenges in
measuring and using WTP values, including framing effects
and ethical objections to asking people directly to value health
improvements. Still, the WTP literature in health care has
grown over the past few decades, with applications to different
disease areas, treatment modalities, and survey methods
[9,11–15].
In particular, the applications of WTP estimation have
emerged for diagnostic testing. Our review examines the per-
ceived value of test information beyond the conventionalociety for Pharmacoeconomics and Outcomes Research (ISPOR).
of Value and Risk in Health, Institute for Clinical Research and
ox #63, Boston, MA 02111, USA.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 9 7 – 8 0 5798cost-effectiveness framework, focusing on the direction and
magnitude of preferences reported in WTP analyses. We also
investigate the methods used to capture preferences and exam-
ine methodological differences across studies to better under-
stand discrepancies in WTP values. Our goal was to understand
how people may value diagnostic tests and how the WTP value
varies with individual factors (e.g., age, income, and disease
history) and test characteristics (e.g., accuracy). Finally, we dis-
cuss how this information can be used to help capture more
completely the value of diagnostic technologies, and the impli-
cations for clinical and policy decisions.Methods
We searched for studies using the PubMed database in January
2012 by inputting the following terms: (willingness to pay OR
contingent valuation) AND diagnostic (n ¼ 500) (Fig. 1). All
English-language articles published from 1985 through 2011
were eligible for screening (n ¼ 486). We screened all articles’
titles and abstracts for potential inclusion. We then obtained
and reviewed the citation list of those articles considered for
potential inclusion to ensure completeness of the PubMed
search. Of these 486 abstracts, we excluded 368 studies that
were cost-effectiveness analyses/cost-utility analyses/cost-
beneﬁt analyses (n ¼ 191), did not assess a diagnostic technol-
ogy (n ¼ 96), did not report any WTP value (n ¼ 42), were
reviews, editorials, or methods (n ¼ 30), or were not eligible for
other reasons (e.g., comprised only study protocols) (n ¼ 9).
Finally, we obtained the full text of the identiﬁed publications
(n ¼ 118) and manually screened the text to select studies that
reported an original WTP estimate for a diagnostic technology.
After review of the full text, an additional 52 articles were
excluded, leaving a ﬁnal sample of 66 studies.
Each WTP article was abstracted by using a standard data
auditing form, which contained three major sections: 1) meth-
odology (e.g., publication information, intervention, type of
diagnostic, disease classiﬁcation, sample, mode of administra-
tion, and elicitation methods); 2) median/mean WTP values; andFig. 1 – Flowchart of the systematic review process.3) factors associated with the WTP estimate. We ﬁrst charac-
terized methodological differences across studies. Then, we
examined individual- and diagnostic-level factors associated
with WTP. Finally, we summarized WTP values across different
diagnostic technologies on the basis of studies that reported
median values.
We also examined whether the WTP studies used one of four
commonly used elicitation methods: 1) discrete-choice questions, 2)
bidding game, 3) payment card, and 4) open-ended questions.
Discrete-choice questions (also referred to as close-ended, dichoto-
mous-choice, or binary questions) present respondents with a WTP
value, which they either accept or reject, often followed by additional
follow-up discrete-choice questions to identify a distribution of WTP
values. A bidding game presents respondents with an initial amount,
which they may either accept or reject and then bid up, or down, in
deﬁned increments until their maximum WTP values are reached.
By asking a series of questions with yes/no bids, the bidding game
methodmay be considered an iterative version of the discrete-choice
method. In contrast to the iterative nature of the bidding game
method, the payment card method presents simultaneously a range
of bids and asks respondents to circle the amount representing the
most they would be willing to pay. Finally, in an open-ended
questionnaire, respondents are asked directly for their maximum
WTP value, without presenting respondents any possible values.Results
The number of published WTP studies pertaining to diagnostic
tests has grown rapidly over time, increasing from 3 published
from 1985 to 1993 to 23 from 2006 to2011 (Table 1). Half of
diagnostic WTP studies have focused on oncology, 16.1% per-
tained to infectious diseases, and 11.7% focused on obstetric or
gynecological conditions. Most laboratory tests were biological
samples (e.g., blood, tissue, and urine)/genetic testing (n ¼ 44,
62.0%) or imaging (n ¼ 23, 31.0%). Biological samples and/or
genetic tests were especially well represented among WTP
studies pertaining to oncology, infectious disease, obstetrics-
gynecology, and neurology (Table 2). Furthermore, imaging tests
were frequently used in oncology and obstetrics/gynecology
studies, but not for infectious disease or endocrinology.
Methodological Differences in WTP Valuation
Mode of administration
Table 1 summarizes methodological differences across the 66
WTP studies. The most common mode of administration was
self-administered questionnaires (36.4%), followed by Web-based
instruments (15.2%), in-person interviews (13.7%), telephone
surveys (13.6%), and mail surveys (7.6%).
Elicitation methods
Approximately one third (30.3%) of the studies used discrete-
choice questions, followed by payment cards (15.2%), bidding
games (13.6%), and open-ended questions (10.6%) (Table 1). Other
studies used more than one contingent valuation method in the
elicitation process [6,16–20] or compared WTP values derived
from different approaches [21–26].
Survey respondent and sample size
Most studies used a sample of patients or at-risk populations
(49.3%), or respondents from the general population (34.5%)
(Table 1). Parents served as proxy respondents for children for
WTP elicitations if children were the subjects of the diagnostic
test [8,27–29]. Other studies compared WTP responses from
different sample populations, such as patients, physicians, man-
aged care organization executives, or the general public [30–34].
Table 1 – Methodological differences in willingness-to-pay valuation of diagnostic technologies.
Study Characteristics Frequency (%) References
Total number or articles reviewed 66
Publication year (n ¼ 66)
1985–1993 3 (4.5%) [47,59,68]
1994–1999 8 (12.1%) [31,52,61,63–65,69,70]
2000–2005 26 (39.4%) [8,20,21,24–26,30,32,33,35,37,42–45,48,50,53,54,56–58,66,71,73]
2006–2011 29 (43.9%) [6,16–19,22,23,27–29,34,36,38–41,46,49,51,55,60,62,67,74-79]
Disease category (n ¼ 68)
Oncology 34 (50.0%) [6,17,18,20–22,24–26,33,36,37,41–43,49–57,60–62,67,68,72,74,76,77,79]
Infection 11 (16.1%) [16,23,31,32,34,40,44,48,70,73,78]
Obstetrics/gynecology 8 (11.7%) [29,35,45,58,59,63–65]
Neurology 5 (7.3%) [6,38,66,69,75]
Musculoskeletal 4 (5.8%) [6,8,39,71]
Endocrinology 2 (2.9%) [28,46]
Other 4 (5.9%) [19,27,30,47]
Type of diagnostic (n ¼ 72)†
Biological sample/genetic testing 44 (61.1%) [6,16–18,20–29,33–38,40,44,48,51,53,58,60,61,63–68,70,72,73,75–79]
Imaging 23 (31.9%) [19,21,24,25,30,42–44,47,49,52,54–57,59,62,69,71,74]
Observational/physiological 3 (4.2%) [8,46,57]
Not speciﬁed 2 (2.8%) [31,32]
Mode of administration (n ¼ 66)
Self-administered 24 (36.4%) [21–25,30–33,40,44,45,51,54,56–58,63,65,70,71,73,78]
Internet 10 (15.2%) [6,18,36,49,55,74–77,79]
Telephone survey 9 (13.6%) [8,17,19,28,35,42,43,53,66]
Interview 9 (13.7%) [26,34,37,38,46–48,59,72]
Self-administered and mail 6 (9.1%) [39,60–62,64,69]
Mail 5 (7.6%) [20,27,29,68]
Unknown 3 (4.5%) [16,52,67]
Elicitation methods (n ¼ 66)
Discrete choice 20 (30.3%) [28–30,35,40,44,46,47,49,51,53–55,58,60,62,72,75,77,79]
More than one method was used 14 (21.2%) [6,16–26]
Payment card 10 (15.2%) [31–33,36–38,61,68,70,74]
Bidding game 9 (13.6%) [8,34,42,43,48,66,69,76,78]
Open-ended questions 7 (10.6%) [27,45,57,59,63–65]
Other/not speciﬁed 6 (9.1%) [39,52,56,67,71,73]
Sample respondents (n ¼ 69)‡
Patient/at-risk population 34 (49.3%) [16,19,21,24–26,31,32,34,35,37,39,44,46–48,51,52,54,56–60,63–65,67–70,73,75]
General population 24 (34.5%) [6,17,18,20,22,23,34,36,42,43,45,49,53,55,62,66,71,72,74,76–79]
Family member 6 (8.7%) [8,27–29,38,61]
Physician 4 (5.8%) [30–33]
Other 3 (3.3%) [31,32,40]
Sample size (n ¼ 66)
1–100 15 (22.3%) [29–31,43,44,47,54,56,58,59,62,67–70,75]
101–500 33 (50.0%) [8,16,17,19,22,23,25,26,28,32,35–38,40,45,46,49,51,52,55,57,63–66,71–74,76–78]
501–1000 7 (10.6%) [20,33,34,48,53,78]
41000 11 (16.7%) [6,18,21,24,27,39,42,60,61,79]
 Neumann et al. [6] examined diagnostic tests for Alzheimer’s disease (neurology), arthritis screening (musculoskeletal), breast cancer
(oncology), and prostate cancer (oncology).
† Frew et al. [21] examined biological and imaging tests (endoscopy) for colorectal cancer screening. Whynes et al. [24] and Frew et al. [25,26]
examined biological and imaging tests. Schiffner et al. [57] examined imaging and observation tests.
‡ Sample respondents of Hirth et al. [31,32] included patients, physicians, and managed care executives. Respondents of Uzochukwu et al. [34]
included patients and individuals from the general population.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 9 7 – 8 0 5 799The sample sizes varied substantially across articles, ranging
from 3 radiologists in one study that evaluated the added value of
biliary contrast [30] to 6352 parents in a study that evaluated WTP
for celiac disease screening [27]. Roughly half of the studies had
samples of 101 to 500 respondents.
Factors Inﬂuencing WTP Values for Diagnostic Technologies
Demographic and socioeconomic characteristics
The association between WTP values and demographic character-
istics varied across studies. Some studies indicated that WTP valueswere positively inﬂuenced by older age [21,35–41], sex [21,25,39], and
majority race/ethnicity [39,42,43], with females and white Ameri-
cans generally having higher WTP values, whereas others found no
relationship between WTP and those characteristics [20,35,44–46].
Most studies indicated that WTP values increased with respondent
income [19–21,26,35,36,38,43,47–50] and education [37–39,47,51].
Disease severity, risk perception, and family history
Disease severity appeared to be positively associated with WTP
values [46,48,52]. In a cohort of 406 adults with type 2 diabetes, for
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 9 7 – 8 0 5800example, patients with severe diabetic retinopathy had signiﬁ-
cantly higher WTP values for screening for diabetic retinopathy
than did patients with mild diabetic retinopathy [46]. In contrast,
a study by Severens et al. [44] found that WTP values were
independent of the perceived severity of the disease in testing
the seroprevalence of antibodies to Histoplasma capsulatum.
Individuals with higher perceived disease risk or who were
more health conscious tended to have higher WTP values for
diagnostic technologies [6,21,37,43,49,53–55]. Neumann et al. [6]
found that WTP values were consistently higher when respond-
ents were presented with an ex ante risk of developing the disease
of 25% compared with 10% and that the results were consistent
across scenarios presenting tests for Alzheimer’s disease, arthri-
tis, breast cancer, and prostate cancer. Another study in Scotland
found that women were willing to pay more for cervical cancer
screening if they were presented with an increased chance of
dying from the disease [41]. In a study of 397 Japanese women
aged 50 to 59 years, WTP values were higher among those who
were more concerned about their health and had received
mammography for breast cancer screening than among women
who had never received mammography [55].
Having family history of the disease, which may affect the
individual’s perceived risk, also was positively associated with
WTP [43,49,53,55]. Wagner et al. [43], for example, found that
women whose sister, mother, or daughter had had cancer were
willing to pay signiﬁcantly more and to travel further to obtain a
free mammogram.
While risk perception was associated with increased WTP
values, it was less clear whether WTP values were inﬂuenced by
prior test results or prior disease status. For example, Liang et al.
[56] reported that women who had prior benign breast diseases
were less willing to pay for a test with 95% accuracy than were
women without the history. In contrast, Stephens et al. [45] found
that while most women (135 of 150 eligible subjects) wanted a
prenatal sonogram during pregnancy, their WTP values and the
number of sonograms they desired did not vary by prior pregnancy.
In addition, WTP values for cervical cancer screening did not vary
by prior smear status in women aged 20 to 59 years in Scotland [20].
Test accuracy
Diagnostic test accuracy generally inﬂuenced both the choice of
the test and the WTP values of the test. One study showed that
although parents generally had a high tolerance for false-positive
newborn screening results, the median WTP values to avoid a
false-positive screening result were signiﬁcantly lower for
parents whose child had experienced a false-positive screening
result ($0) than for parents of children with normal screening
results ($100) (P o 0.001) [28]. Liang et al. [56] found that women
were willing to pay an average of $611 to have a new noninvasive
breast cancer diagnostic test instead of a biopsy if the test was as
accurate as biopsy; however, WTP values decreased to $308 if the
test had only 95% accuracy. In a survey of 175 female patients,
Raab et al. [37] estimated an increased median WTP from $50 to
$100 as the performance of a new Papanicolaou test increased,
regardless of their perceived risk of cervical cancer. Schiffner
et al. [57] reported that the WTP value for a standard practice in
detecting malignant melanoma was at least 40% below that of a
hypothetical test with perfect accuracy [57].
Median WTP Values of Diagnostic Tests
Table 3 provides speciﬁc examples selected from the 44 studies
that reported median WTP values. Most reported median WTP
values below $100. Within this range of WTP values, there was
wide variation in test complexity, from simple contrast agent
imaging [30] to positron emission tomography screening [36,49].
Similarly, these WTP values contained a variety of diseases for
Table 3 – Selected median WTP values of diagnostic tests.
Median WTP value ($) Disease category Diagnostic test References
0–100 Infection [H. Pylori] test for peptic ulcers [31,32,70]
Malaria testing [34,48]
HIV testing [78]
Combination TB, HIV, and syphilis [16]
Musculoskeletal Osteoporosis screening [71]
Oncology
Cervical cancer screening [68]
Colon cancer screening [21,24,25,50,60,61]
Prostate -speciﬁc antigenscreening [18,55,76,79]
Breast cancer genetic screening [33,55]
Malignant melanoma screening [57]
PET screening for unspeciﬁc cancer [36,49]
Florescent oral cancer screening [67]
Obstetrics/
gynecology
Antenatal screening for cystic ﬁbrosis
[63–65]
Other Contrast agent in imaging of biliary tree [30]
Celiac disease screening [27]
101–500
Endocrinology Newborn screening for metabolic disorders [28]
Musculoskeletal
DXA scan for osteoporosis screening [39]
Arthritis screening [6]
Oncology Prostate cancer screening [6]
Breast cancer screening [6]
Colon cancer screening [22,62]
Neurology Hypothetical blood test to identify Alzheimer’s disease [6,38,66]
Other MRI/CT angiography [19]
501–1000 NA
41000
Oncology
Colon cancer screening [25,26]
PET for suspected lung cancer [52,54]
Colon cancer screening [25,26]
Obstetrics/
gynecology
Prenatal ultrasound [59]
Amniocentesis for chromosomal disorders [35]
Genetic prenatal testing for idiopathic developmental
disability
[29]
Karyotype analysis for Down’s syndrome [58]
CT, [X-ray] computed tomography; DXA, dual-energy X-ray absorbtiometry; HIV, human immunodeﬁciency virus; MRI, magnetic resonance
imaging; NA, not applicable/available; PET, positron emission tomography; TB, tuberculosis; WTP, willingness to pay.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 9 7 – 8 0 5 801which to test. Most diagnostics for infectious diseases and
sexually transmitted diseases were estimated to have WTP
values of less than $100.
Among technologies with median WTP values in the range of
$101 to $500, the majority of the diagnostic tests were for cancer.
Interventions represented within this WTP value range generally
used more complicated modalities (e.g. magnetic resonance
imaging [19], dual-energy x-ray absorptiometry [39], and mam-
mography [6]) than did those with a WTP value below $100.
Several diseases associated with aging were represented in this
WTP value range, such as some cancers, osteoporosis, arthritis,
and Alzheimer’s disease.
Finally, eight studies reported median WTP values greater
than $1000. These studies examined diagnostic technologies
relevant to cancer [25,26,52,54] and to expectant parents (e.g.,
karyotype analysis for Down’s syndrome [58], prenatal ultra-
sound [59], amniocentesis for chromosomal disorders [35], and
genetic prenatal test for developmental disability [29]).
To further understand discrepancies in WTP values, we exam-
ined studies that evaluated similar diagnostic technologies, using
colon or colorectal cancer screening as an example. Table 4
summarizes characteristics of nine articles related to colon and
colorectal cancer screening, including biological (e.g., fecal occult
blood, colonoscopy) and imaging (e.g., computed tomography
colonography, endoscopy) tests. Depending on the elicitation
methods, six studies reported median WTP values below $100[21,24,25,50,60,61], two reported median WTP values between $100
and $500 [22,62], and two reported median WTP values over $1000
[25,26]. One study by Frew et al. [25] identiﬁed a large difference
between open-ended and close-ended WTP questions for color-
ectal cancer screening. Depending on the starting bid (larger
starting bids having larger mean WTP estimates), the median
WTP estimate could be 20 times as large for close-ended (£946–
£1009) compared with open-ended questions (£30–£50) [25].Discussion
We reviewed published WTP studies pertaining to diagnostic
technologies over the past three decades. The number of studies
has grown steadily, with more than half focused on cancer. Most
of these WTP studies examined diagnostics by using biological
samples or genetic testing. However, a great variation exists in
the type of technologies assessed, disease of interest, respondent
characteristics, and study methodology—all of which may inﬂu-
ence the perceived value of a diagnostic test.
Despite numerous cost-utility analyses demonstrating good
value for money of many laboratory diagnostic tests, relatively
little has been published characterizing preferences for test
information in detail—speciﬁcally, how preferences vary by
patient factors, the condition being evaluated, or the diagnostic
modality. Our review suggests that at the individual level,
Table 4 – WTP studies for colon and colorectal cancer screening.
Study Intervention Type of diagnostic Sample (country of study) Mode of
administration
Elicitation
methodology
WTP values (2011 US $)
Median WTP value ≤ $100
Petersen et al. [61] Colon cancer
gene testing
Biological/genetic 1286 relatives of persons with
colon cancer or died from
colon cancer (US)
Mailed and
self-administered
Payment scale o$50
Frew et al. [21] Colorectal cancer
screening
Biological/imaging
(endoscopy)
2767 patients (UK) Self-administered Open-ended/
Payment scale
50–89
Frew et al. [25] Colorectal cancer
screening
Biological/imaging
(endoscopy)
354 patients (UK) Self-administered Open-ended 65(fecal occult blood test) to
109 (ﬂexible sigmoidoscopy)
Whynes et al. [24] Colorectal cancer
screening
Biological/imaging 2767 patients (UK) Self-administered Open-ended/
Payment scale
109
Whynes et al. [50] Colorectal cancer
screening
Biological (FOB test)/
imaging
(endoscopy)
1401 patients (UK) Self-administered Payment scale 91–114
Howard and
Salkeld [60]
Colorectal cancer
screening
Biological (FOB test) 1157 people have previously
purchased an FOB test
(Australia)
Mail and
self-administered
Discrete-choice 6.65–11.85 for extra cancer
found, 5.10–$10.15 for missed
cancer avoided
Median WTP value $100–$500
Ho et al. [62] Colorectal cancer
screening
Imaging (CT
colonography)
68 people older than 50 y who
had been offered other
screening and refused (US)
Mail and
self-administered
Discrete-choice 155
Jonas et al. [22] Colon cancer
screening
Biological
(colonoscopy)
110 people aged 50–85 y with
no colon cancer history (US)
Self-administered Open-ended 207
Jonas et al. [22] Colon cancer
screening
Biological
(colonoscopy)
110 people aged 50–85 y with
no colon cancer history (US)
Self-administered Payment scale 103–257
Median WTP value 4 $1000
Frew et al. [25] Colorectal cancer
screening
Biological/imaging
(endoscopy)
354 patients (UK) Self-administered Close-ended 2053 (fecal occult blood); 2191
(ﬂexible sigmoidoscopy)
Frew et al. [26] Colorectal cancer
screening
Biological/imaging
(endoscopy)
106 patients (UK) Interviews Open-ended/
Payment scale
1151 for ﬂexible sigmoidoscopy
and fecal occult blood when
bids start between 23 and
1151; 2302 when starting at
2302
CT, [X-ray] computed tomography; FOB, fecal occult blood; WTP, willingness to pay.
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V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 7 9 7 – 8 0 5 803differences in risk perception, risk tolerance, and personal or
family/acquaintance history may make some individuals more
willing to pay larger amounts of money to identify whether they
have a disease or risk factor. At the disease level, more severe
conditions and diseases without a controllable risk factor, such as
some cancers and congenital abnormalities, are associated with
higher WTP estimates; colon cancer diagnosis [21,22,24–26,50,60–
62] and perinatal screening [28,29,35,63–65] are examples. Fur-
ther, at the technology level, more accurate tests tend to have
higher WTP estimates [6,56,60,66], suggesting that they are
perceived as having more use for medical decision making and
perhaps for greater reductions in diagnostic uncertainty.
Our review also showed that comparatively simple imaging
methods (e.g., contrast agents [30] and ﬂuorescence methods [67])
generally have lower WTP estimates than do more technologi-
cally complicated imaging modalities (e.g., positron emission
tomography [52,54] and magnetic resonance imaging [19]). This
may not be due to patients’ inherent preference for complicated
technologies, but rather the perception that the tests have better
diagnostic accuracy.
The perceived value of diagnostic technologies also seems to
be inﬂuenced by the study design and elicitation methods, even
for similar laboratory tests. Our review of studies related to colon
and colorectal cancer screening found substantial differences in
median WTP values, ranging from $100 or less [21,24,25,50,60,61]
to more than $1000 [25,26]. Although several potential explan-
ations for the WTP difference have been suggested (e.g., framing
and anchoring), research to date has not yet identiﬁed which, if
any, are most impactful. It is also not clear which of the
elicitation methods provides a more accurate estimate of max-
imumWTP value or a reproducible method, or yields consistently
higher/lower values than others. For instance, among articles
comparing different contingent valuation methods, one study
reported higher WTP values (for Chlamydia screening [23]) from
discrete-choice questions than from payment cards, while two
studies reported higher WTP values (for colorectal cancer screen-
ing [21,24,50]) for payment cards than for open-ended questions.
Another study, however, reported identical median WTP values
for colorectal screening for payment cards and open-ended
questions, though increased WTP values for discrete-choice
questions [25]. That same researcher, in a later analysis [26],
reported higher WTP values for a bidding game than for either
payment scale or open-ended questions. Our ﬁndings highlight
the need for evaluating how different WTP elicitation techniques
(e.g., bidding game and open ended questions) and design
features (e.g., staring bid and various qualiﬁers used to prime
the open-ended question) may inﬂuence results and cross-study
comparability.
Because WTP studies offer a conceptually appealing approach
to attaching a value to a diagnostic medical technology, they
could help inform the setting of prices or insurance co-pays, and
be incorporated in economic evaluations of new diagnostics,
such as cost-beneﬁt analysis [8,9]. Previous research has sug-
gested that they may help demonstrate the value for diagnostics
not only to improve medical decision making but also to beneﬁt
patients irrespective of treatment by reducing uncertainty [5,6].
For WTP to be informative, however, there must be a level of
validity and reliability to the WTP measurement. A need for
further research is underscored by the differences in WTP
estimates produced when different methods were used to esti-
mate WTP for the same test (e.g., colon cancer screening).
There are some limitations to our review. First, focusing on
WTP values for treatments and interventions, rather than diag-
nostics, may lead to different conclusions about the compara-
bility of various WTP methods. Comparing WTP values for
diagnostics and treatments or interventions is outside the scope
of this study. Second, our summary of WTP values was limited toa subset of articles that reported median values. Nonreporting of
median results in approximately one third of the articles, and
variation in study methodologies made comparisons across
studies difﬁcult. Third, WTP values depend on income and
therefore may vary by country. In our analysis of colon and
colorectal cancer screening, among studies reporting median
WTP values of $100 or less, one was conducted in the United
States [61], four in the United Kingdom [21,24,25,50], and one in
Australia [60]. Both studies that reported median WTP values
between $100 and $500 used a US sample [22,62], and both studies
that reported median WTP values over $1000 used a UK sample
[25,26]. More research on whether geographical or jurisdictional
factors inﬂuence WTP would be helpful.
Our review adds to current understanding about the value of
diagnostic technologies beyond the conventional cost-effectiveness
framework. Our ﬁndings also shed light on discrepancies in
preferences for and value of test information with respect to
individual characteristics, the disease in question, as well as the
performance characteristics of the test. Despite its limitations, WTP
analysis provides a standard, well-accepted approach to capturing
preferences, which can be used to inform whether a technology
represents good value for money. Further research is needed to
identify the relative accuracy, precision, and pros and cons of
various WTP measurement techniques, as suggested by great
variation in WTP estimates across studies examining colon and
colorectal cancer screening [21,22,24–26,50,60–62]. In addition, fur-
ther research is needed to identify how methodological choice and
population sampled can result in differences in WTP estimates.
Such research would be helpful to generate guidelines and “best
practices” that can help guide the WTP ﬁeld to inform decision
makers. This research could assist decision makers in using the
information created by WTP studies to align the prices and co-
payments for diagnostic medical technologies more closely to the
total value generated by their use.Acknowledgment
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